Rheumatoid arthritis instances that have RANKL (receptor activator of nuclear factor kappa ligand) methylation

Ola M Gharbia


Rheumatoid arthritis (RA) is an autoimmune seditious complaint characterized by sinusitis, cartilage damage and bone resorption. Methylation of deoxyribonucleic acid plays a pivotal part in repressing gene expression. Receptor activator of nuclear factor- kappa ligand (RANKL) controls bone homeostasis.

Aim of the work

To assess the serum position of RANKL and its gene protagonist methylation in RA cases and to determine its association with clinical characteristics and complaint exertion.

Cases and styles

The study included 40 RA cases and 40 controls. The complaint exertion score (DAS28) was assessed. Frequence of RANKL gene protagonist methylation was determined by quantitative methylation specific PCR (QMSP) and serum RANKL position by enzyme linked immunosorbent assay (ELISA).


Cases mean age was46.8 ±10.6 times, 36 ladies and 4 males (F M 91) with median complaint duration4.5 times. Positive rheumatoid factor, anti-cyclic citrullinated peptide and C- reactive protein were present in 65, 75 and 55 of cases. Methylation chance of RANKL gene protagonist was significantly lower in cases(3.4) than in controls(3.7)( p = 0.035) while serum position was significantly increased in cases(9.1 ng/ ml,5.3 –11.8 ng/ ml) than in controls(5.7 ng/ ml,4.5 – 8 ng/ ml)( p = 0.003). RANKL methylation frequence was equally associated with serum position (rs = -0.21, p = 0.06). There was no significant correlation of RANKL serum position and methylation with DAS28 (r = 0.03, p = 0.87 and r = 0.06, p = 0.73 independently). RANKL serum position (>9.5 ng/ ml) and methylation chance (≤ 9) significantly distinguish RA cases from control (perceptivity47.5, particularity91.9; p = 0.001 and perceptivity 100, particularity 40; p = 0.03 independently).


RA cases expressed elevated serum RANKL with low methylation.